Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial

The Lancet Infectious Diseases

Volumn 13, Issue 5, 2013, Pages 401-408

  Lawitz, Eric ^a   Lalezari, Jay P ^b   Hassanein, Tarek ^c   Kowdley, Kris V ^d   Poordad, Fred F ^e   Sheikh, Aasim M ^f   Afdhal, Nezam H ^g   Bernstein, David E ^h   DeJesus, Edwin ⁱ   Freilich, Bradley ^j   Nelson, David R ^k   Dieterich, Douglas T ^l   Jacobson, Ira M ^m   Jensen, Donald ⁿ   Abrams, Gary A ^o   Darling, Jama M ^p   Rodriguez Torres, Maribel ^q   Reddy, K Rajender ^r   Sulkowski, Mark S ^s   Bzowej, Natalie H ^t   Hyland, Robert H ^u   Mo, Hongmei ^u   Lin, Ming ^u   Mader, Michael ^v   Hindes, Robert ^w   Albanis, Efsevia ^l   Symonds, William T ^u   Berrey, Michelle M ^x   Muir, Andrew ^y   more..

^a Texas Liver Institute   (United States)

^b Quest Clinical Research   (United States)

^c Southern California Liver Centers   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f Georgia Cancer Specialists   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h NORTH SHORE UNIVERSITY HOSPITAL   (United States)

ⁱ ORLANDO IMMUNOLOGY CENTER   (United States)

^j Kansas City Gastroenterology and Hepatology   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l MOUNT SINAI HOSPITAL   (United States)

^m Department of Obstetrics Gynecology   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o Alabama Liver and Digestive Specialists   (United States)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t OCHSNER MEDICAL CENTER   (United States)

^u GILEAD SCIENCES   (United States)

^v M Pharma Clinical Consulting   (United States)

^w Gilead Sciences   (United States)

^x Chimerix Inc   (United States)

^y DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR;

ADULT; AGED; ANEMIA; APHTHOUS ULCER; ARTHRALGIA; ARTICLE; CHILL; CONFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; FOLLICULITIS; HEART INFARCTION; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDAL IDEATION; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEADACHE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NAUSEA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84876740954     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70033-1     Document Type: Article

References (23)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
2. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
3. Assis DN, Lim JK New pharmacotherapy for hepatitis C. Clin Pharm Ther 2012, 92:294-305.
4. Kiser JJ, Burton JR, Anderson PL, Everson GT Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012, 55:1620-1628.
5. Fox AN, Jacobson IM Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clin Infect Dis 2012, 55(suppl 1):S16-S24.
6. Pearlman BL Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012, 12:717-728.
7. Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010, 54:3187-3196.
8. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010, 285:34337-34347.
9. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012, 56:3359-3368.
10. Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005, 49:2059-2069.
11. Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob Agents Chemother 2008, 52:3523-3531.
12. Lawitz E, Lalezari J, Rodriguez-Torres M, et al. High rapid virologic response (RVR) with PSI-7977 QD plus PEG-IFN/RBV in a 28-day phase 2a trial. Hepatology 2010, 52(suppl):706A.
13. Gane E, Stedman C, Hyland R, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
15. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
16. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
17. Jacobson IM, Lawitz E, Lalezari J, et al. GS-7977 400 mg QD safety and tolerability in the over 500 patients treated for at least 12 weeks. J Hepatol 2012, 56(suppl 2):S441.
18. Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2012, published online Aug 13. 10.1111/j.1365-2125.2012.04419.x.
19. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
20. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
21. Hoofnagle JH, Seeff LB Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006, 355:2444-2451.
22. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
23. Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days. J Hepatol 2012, 56(suppl 2):S445-S446.